 Home > Active Ingredient News > Study of Nervous System > JAMA Neurol: Serum N-acetylglucosamine or an important marker of multiple sclerosis disease progression

JAMA Neurol: Serum N-acetylglucosamine or an important marker of multiple sclerosis disease progression

 Last Update: 2021-06-04
 Source: Internet
 Author: User

Tags

low protein levels

baclofen multiple sclerosis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Multiple sclerosis (MS) is a neurological dysfunction caused by inflammatory demyelination, while progressive MS (PMS) is characterized by persistent inflammation, remyelination failure and progressive neurodegeneration, which ultimately leads to irreversible neurological disability.

Recently, researchers investigated the correlation between the serum levels of endogenous glycans in patients with multiple sclerosis and the symptoms of MS.

This study is a cross-sectional validation study conducted in two research centers in the United States and Germany.

The development cohort included 66 healthy controls (38 women; average age 42 years), 33 patients with relapsing-remitting MS (RRMS) (25 women, average age 50 years), and 21 cases of progressive multiple sclerosis (PMS) Patients (14 women, average age 55 years).

In the development of the queue, the average serum levels of the control group GlcNAc and its stereoisomers (HexNAc) is 710nm, RRMS patients 682nM, and PMS patients compared with healthy controls and RRMS groups, GlcNAc levels were significantly reduced (of 548 nm) in In the development cohort, the average serum level of GlcNAc and its stereoisomer (HexNAc) in the control group was 710 nM, and in RRMS patients was 682 nM.

HexNAc level and clinical symptoms of MS

Studies believe that serum N-acetylglucosamine deficiency or an important biomarker of progressive multiple sclerosis, GlcNAc deficiency may be related to the progressive disease and neurodegeneration of MS patients .

Serum N-acetylglucosamine deficiency or an important biomarker of advanced multiple sclerosis, GlcNAc deficiency may be related to the progressive disease and neurodegeneration of MS patients.

Original source:

Alexander U.

Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.
JAMA

is here to leave a message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.